This HTML5 document contains 120 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
n9http://dx.doi.org/10.1161/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q38439752
rdf:type
wikibase:Item
schema:description
vitskapeleg artikkel artikel ilmiah scientific article published on 09 December 2013 2013年论文 scienca artikolo บทความทางวิทยาศาสตร์ 2013年論文 2013年论文 artikulong pang-agham articol științific article scientifique 2013年论文 научна статия tieteellinen artikkeli artículo científico vitenskapelig artikkel 2013年の論文 vetenskaplig artikel artigo científico научни чланак scientific article published on 09 December 2013 სამეცნიერო სტატია bilimsel makale مقالة علمية نشرت في 09 ديسمبر 2013 bài báo khoa học 2013년 논문 2013年論文 2013年論文 artikull shkencor videnskabelig artikel vědecký článek artigo científico vedecký článok wetenschappelijk artikel наукова стаття, опублікована в грудні 2013 2013年論文 artykuł naukowy বৈজ্ঞানিক নিবন্ধ tudományos cikk artigo científico scientific article published on 09 December 2013 мақолаи илмӣ 2013年论文 article scientific научни чланак articolo scientifico naučni članak επιστημονικό άρθρο article científic 2013年论文 wissenschaftlicher Artikel 2013年论文 научная статья 2013 nî lūn-bûn מאמר מדעי artículu científicu espublizáu en 2013 2013年論文 teaduslik artikkel
p:P577
wds:Q38439752-54579726-9740-40C3-8EAE-C81D21BECF8A
wdt:P577
2013-12-09T00:00:00Z
p:P407
wds:Q38439752-A95C2A9F-63BA-43C6-AE3E-1922352C4533
wdt:P407
wd:Q1860
p:P2093
wds:Q38439752-C8796FF8-FBAB-4F41-9755-A572DD565CBD wds:Q38439752-3C6AA70C-B6C2-471B-B4C7-3B75E81465EF
wdt:P2093
Stuart J Connolly Ulrika Andersson
rdfs:label
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis
skos:prefLabel
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis
schema:name
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis
p:P50
wds:Q38439752-0F047208-689E-4B62-B1CF-166A54A4B2A2 wds:Q38439752-1BA47D77-09ED-4FEA-9DB4-342E8ADB6B11 wds:Q38439752-25429C79-400A-42F3-9D02-292C9B2F81E0 wds:Q38439752-37785397-8004-44B8-873B-9C0244600F5E wds:Q38439752-3DB310AA-BC63-4522-BEEB-E539DC793564 wds:Q38439752-6943308B-ABC9-4A02-B334-41A197F848AB wds:Q38439752-A641623E-9739-4FB6-82B8-CEFE6B89A429 wds:Q38439752-E323FC73-4EFF-44C0-A46B-21E612DFEC0B wds:Q38439752-E9B09C2D-C304-4B88-A37A-CEF6F61EDB3B
wdt:P50
wd:Q42846212 wd:Q110902282 wd:Q106086753 wd:Q110902934 wd:Q2214381 wd:Q43407505 wd:Q6230815 wd:Q51505621 wd:Q114427140
p:P1476
wds:Q38439752-5FE25E8A-FCA0-4617-892C-B4BFD8418768
wdt:P1476
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis
p:P304
wds:Q38439752-FC0CD7E9-345F-4DCB-9BDF-8F8F48DB4FB7
wdt:P304
961-970
p:P31
wds:Q38439752-3A2DBEFA-836D-4442-96C2-D8C3AFFC7D11
wdt:P31
wd:Q13442814
p:P921
wds:Q38439752-60F57EBC-DC96-4275-B744-C974593CAA30 wds:Q38439752-F9AC58C0-5D31-426B-B8B1-BD28068A44BB wds:Q38439752-0F9ADDED-CD24-401D-B329-67AA0522DF45 wds:Q38439752-1CC5DCCC-0DB0-4F1F-A958-99FF852A3DB1
wdt:P921
wd:Q63279445 wd:Q407431 wd:Q815819 wd:Q419345
p:P698
wds:Q38439752-D199F414-3068-4648-8244-E58E11A1022A
wdtn:P698
n7:24323795
wdt:P698
24323795
p:P1433
wds:Q38439752-95D92CA3-AC51-4AD2-B9AD-BC4F9DDD3A32
wdt:P1433
wd:Q578091
p:P433
wds:Q38439752-B5C7B725-9107-4B4F-88FA-F854E1358954
p:P478
wds:Q38439752-9373BB61-3F7C-4AB2-95F3-5C9E248C9617
wdt:P433
9
wdt:P478
129
p:P356
wds:Q38439752-90D113D1-E9CE-48C9-A97F-0833A085E3E8
wdtn:P356
n9:CIRCULATIONAHA.113.003628
wdt:P356
10.1161/CIRCULATIONAHA.113.003628